{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:08:30Z","timestamp":1760123310416},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,6,3]]},"DOI":"10.7759\/cureus.61562","type":"journal-article","created":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T09:15:15Z","timestamp":1717406115000},"source":"Crossref","is-referenced-by-count":2,"title":["Tenofovir-Associated Kidney Dysfunction and Bone Fracture: A Case Report and Literature Review"],"prefix":"10.7759","author":[{"given":"KK","family":"Athish","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shobhana","family":"Nayak Rao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Venkat H","family":"Marimuthu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vamsi","family":"Krishna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anwadevi","family":"Arun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Adverse effects of antiretroviral therapy for HIV infection","volume":"170","author":"Montessori V","year":"2004","unstructured":"Montessori V, Press N, Harris M, Akagi L, Montaner JS. Adverse effects of antiretroviral therapy for HIV infection. CMAJ. 2004, 170:229-38.","journal-title":"CMAJ"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1590\/S1678-9946202264010","article-title":"Tenofovir-induced renal and bone toxicity: report of two cases and literature review","volume":"64","author":"Fioroti CE","year":"2022","unstructured":"Fioroti CE, Distenhreft JI, Paulino BB, Lacchine K, Ramos DR, Seguro AC, Luchi WM. Tenofovir-induced renal and bone toxicity: report of two cases and literature review. Rev Inst Med Trop Sao Paulo. 2022, 64:e10. 10.1590\/S1678-9946202264010","journal-title":"Rev Inst Med Trop Sao Paulo"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1177\/2325958220919231","article-title":"A review and clinical understanding of tenofovir: tenofovir disoproxil fumarate versus tenofovir alafenamide","volume":"19","author":"Wassner C","year":"2020","unstructured":"Wassner C, Bradley N, Lee Y. A review and clinical understanding of tenofovir: tenofovir disoproxil fumarate versus tenofovir alafenamide. J Int Assoc Provid AIDS Care. 2020, 19:10.1177\/2325958220919231","journal-title":"J Int Assoc Provid AIDS Care"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1086\/511683","article-title":"The incidence and natural history of osteonecrosis in HIV-infected adults","volume":"44","author":"Morse CG","year":"2007","unstructured":"Morse CG, Mican JM, Jones EC, Joe GO, Rick ME, Formentini E, Kovacs JA. The incidence and natural history of osteonecrosis in HIV-infected adults. Clin Infect Dis. 2007, 44:739-48. 10.1086\/511683","journal-title":"Clin Infect Dis"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/hr.2012.159","article-title":"Pathophysiology of the aging kidney and therapeutic interventions","volume":"35","author":"Kanasaki K","year":"2012","unstructured":"Kanasaki K, Kitada M, Koya D. Pathophysiology of the aging kidney and therapeutic interventions. Hypertens Res. 2012, 35:1121-8. 10.1038\/hr.2012.159","journal-title":"Hypertens Res"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.12878","article-title":"2019 update of the European AIDS Clinical Society Guidelines for treatment of people living with HIV version 10.0","volume":"21","author":"Ryom L","year":"2020","unstructured":"Ryom L, Cotter A, De Miguel R, et al.. 2019 update of the European AIDS Clinical Society Guidelines for treatment of people living with HIV version 10.0. HIV Med. 2020, 21:617-24. 10.1111\/hiv.12878","journal-title":"HIV Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3390\/pharmacy10060164","article-title":"Long-term evaluation of changes in kidney function after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in patients living with HIV","volume":"10","author":"Gilbert JM","year":"2022","unstructured":"Gilbert JM, Vest K, Kish TD. Long-term evaluation of changes in kidney function after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in patients living with HIV. Pharmacy (Basel). 2022, 10:164. 10.3390\/pharmacy10060164","journal-title":"Pharmacy (Basel)"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-023-03027-4","article-title":"Renal and bone side effects of long-term use of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide fumarate in patients with hepatitis B: a network meta-analysis","volume":"23","author":"Liu Z","year":"2023","unstructured":"Liu Z, Zhao Z, Ma X, Liu S, Xin Y. Renal and bone side effects of long-term use of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide fumarate in patients with hepatitis B: a network meta-analysis. BMC Gastroenterol. 2023, 23:384. 10.1186\/s12876-023-03027-4","journal-title":"BMC Gastroenterol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.4102\/sajhivmed.v19i1.817","article-title":"An overview of tenofovir and renal disease for the HIV-treating clinician","volume":"19","author":"Venter WD","year":"2018","unstructured":"Venter WD, Fabian J, Feldman C. An overview of tenofovir and renal disease for the HIV-treating clinician. South Afr J HIV Med. 2018, 19:817. 10.4102\/sajhivmed.v19i1.817","journal-title":"South Afr J HIV Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1086\/598507","article-title":"Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study","volume":"48","author":"Rodr\u00edguez-N\u00f3voa S","year":"2009","unstructured":"Rodr\u00edguez-N\u00f3voa S, Labarga P, Soriano V, et al.. Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study. Clin Infect Dis. 2009, 48:e108-16. 10.1086\/598507","journal-title":"Clin Infect Dis"},{"key":"ref11","doi-asserted-by":"crossref","DOI":"10.1177\/135965350701200704","article-title":"Mitochondrial toxicity of tenofovir, emtricitabine and abacavir alone and in combination with additional nucleoside reverse transcriptase inhibitors","volume":"12","author":"Venhoff N","year":"2007","unstructured":"Venhoff N, Setzer B, Melkaoui K, Walker UA. Mitochondrial toxicity of tenofovir, emtricitabine and abacavir alone and in combination with additional nucleoside reverse transcriptase inhibitors. Antivir Ther. 2007, 12:1075-85.","journal-title":"Antivir Ther"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2017.0003","article-title":"Efficacy of tenofovir-based rescue therapy for chronic hepatitis B patients with resistance to lamivudine and entecavir","volume":"23","author":"Jeon HJ","year":"2017","unstructured":"Jeon HJ, Jung SW, Park NH, et al.. Efficacy of tenofovir-based rescue therapy for chronic hepatitis B patients with resistance to lamivudine and entecavir. Clin Mol Hepatol. 2017, 23:230-8. 10.3350\/cmh.2017.0003","journal-title":"Clin Mol Hepatol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e3181d05579","article-title":"Incomplete reversibility of tenofovir-related renal toxicity in HIV-infected men","volume":"55","author":"Wever K","year":"2010","unstructured":"Wever K, van Agtmael MA, Carr A. Incomplete reversibility of tenofovir-related renal toxicity in HIV-infected men. J Acquir Immune Defic Syndr. 2010, 55:78-81. 10.1097\/QAI.0b013e3181d05579","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1089\/AID.2011.0052","article-title":"Early changes in parathyroid hormone concentrations in HIV-infected patients initiating antiretroviral therapy with tenofovir","volume":"28","author":"Masi\u00e1 M","year":"2012","unstructured":"Masi\u00e1 M, Padilla S, Robledano C, L\u00f3pez N, Ramos JM, Guti\u00e9rrez F. Early changes in parathyroid hormone concentrations in HIV-infected patients initiating antiretroviral therapy with tenofovir. AIDS Res Hum Retroviruses. 2012, 28:242-6. 10.1089\/AID.2011.0052","journal-title":"AIDS Res Hum Retroviruses"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0000000000000248","article-title":"Tenofovir and bone health","volume":"11","author":"Grant PM","year":"2016","unstructured":"Grant PM, Cotter AG. Tenofovir and bone health. Curr Opin HIV AIDS. 2016, 11:326-32. 10.1097\/COH.0000000000000248","journal-title":"Curr Opin HIV AIDS"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01096-13","article-title":"Association of higher plasma vitamin D binding protein and lower free calcitriol levels with tenofovir disoproxil fumarate use and plasma and intracellular tenofovir pharmacokinetics: cause of a functional vitamin D deficiency?","volume":"57","author":"Havens PL","year":"2013","unstructured":"Havens PL, Kiser JJ, Stephensen CB, et al.. Association of higher plasma vitamin D binding protein and lower free calcitriol levels with tenofovir disoproxil fumarate use and plasma and intracellular tenofovir pharmacokinetics: cause of a functional vitamin D deficiency?. Antimicrob Agents Chemother. 2013, 57:5619-28. 10.1128\/AAC.01096-13","journal-title":"Antimicrob Agents Chemother"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.7326\/M14-1409","article-title":"Vitamin D and calcium attenuate bone loss with antiretroviral therapy initiation: a randomized trial","volume":"162","author":"Overton ET","year":"2015","unstructured":"Overton ET, Chan ES, Brown TT, et al.. Vitamin D and calcium attenuate bone loss with antiretroviral therapy initiation: a randomized trial. Ann Intern Med. 2015, 162:815-24. 10.7326\/M14-1409","journal-title":"Ann Intern Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1086\/644769","article-title":"Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-lamivudine: a randomized, 96-week trial","volume":"49","author":"Martin A","year":"2009","unstructured":"Martin A, Bloch M, Amin J, Baker D, Cooper DA, Emery S, Carr A. Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-lamivudine: a randomized, 96-week trial. Clin Infect Dis. 2009, 49:1591-601. 10.1086\/644769","journal-title":"Clin Infect Dis"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3280b07b33","article-title":"The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years","volume":"21","author":"Nelson MR","year":"2007","unstructured":"Nelson MR, Katlama C, Montaner JS, et al.. The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. AIDS. 2007, 21:1273-81. 10.1097\/QAD.0b013e3280b07b33","journal-title":"AIDS"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2010.318","article-title":"Tenofovir nephrotoxicity: acute tubular necrosis with distinctive clinical, pathological, and mitochondrial abnormalities","volume":"78","author":"Herlitz LC","year":"2010","unstructured":"Herlitz LC, Mohan S, Stokes MB, Radhakrishnan J, D'Agati VD, Markowitz GS. Tenofovir nephrotoxicity: acute tubular necrosis with distinctive clinical, pathological, and mitochondrial abnormalities. Kidney Int. 2010, 78:1171-7. 10.1038\/ki.2010.318","journal-title":"Kidney Int"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/258294-tenofovir-associated-kidney-dysfunction-and-bone-fracture-a-case-report-and-literature-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T09:15:18Z","timestamp":1717406118000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/258294-tenofovir-associated-kidney-dysfunction-and-bone-fracture-a-case-report-and-literature-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,3]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.61562","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6,3]]}}}